Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.
Gao J, Hu J, Yu F, Wang C, Sheng D, Liu W, Hu A, Yu K, Xiao X, Kuang Y, Zacksenhaus E, Gajendran B, Ben-David Y.
Gao J, et al. Among authors: zacksenhaus e.
BMC Cancer. 2023 Apr 4;23(1):306. doi: 10.1186/s12885-023-10742-4.
BMC Cancer. 2023.
PMID: 37016335
Free PMC article.